Prostate Brachytherapy $5,381 Payment Rate Inadequate – Stakeholders
This article was originally published in The Gray Sheet
Executive Summary
CMS will need to determine whether the two isotopes used in prostate brachytherapy are cost equivalent before the agency publishes its 2003 hospital outpatient prospective payment system (OPPS) final rule on Nov. 1
You may also be interested in...
OPPS Rule Establishes Separate Palladium, Iodine G Codes For Brachytherapy
The Centers for Medicare & Medicaid Services will establish two new G codes to track prostate brachytherapy procedures, under the 2003 hospital outpatient prospective payment system final rule
OPPS Rule Establishes Separate Palladium, Iodine G Codes For Brachytherapy
The Centers for Medicare & Medicaid Services will establish two new G codes to track prostate brachytherapy procedures, under the 2003 hospital outpatient prospective payment system final rule
Prostate Brachytherapy Sources Vary By $5,570, Violate 2X Rule – CAB Data
Brachytherapy seeds for prostate cancer should be reimbursed by Medicare on a per-seed basis under the hospital outpatient prospective payment system, the Coalition for the Advancement of Brachytherapy (CAB) contends in Sept. 24 comments to CMS